Literature DB >> 16980082

C4d: a marker for hepatic transplant rejection.

R Lorho1, B Turlin, N Aqodad, N Triki, A S de Lajarte-Thirouard, C Camus, M Lakehal, P Compagnon, E Dupont-Bierre, B Meunier, K Boudjema, M Messner.   

Abstract

BACKGROUND: Acute rejection is still a common complication of hepatic transplantation. The diagnosis, based on the histological examination of the graft, may be difficult to confirm in the setting of combined hepatitis C virus infection. The presence of C4d in the portal capillaries could facilitate differentiation between acute rejection and relapsed hepatitis C. The deposit of C4d provides evidence of activation of humoral immunity. To attempt to confirm this hypothesis, we searched for the presence of C4d in posttransplant hepatic biopsies.
METHODS: Thirty-six biopsies from 34 patients were analyzed retrospectively. The samples had been requested for one of the following reasons: suspected rejection, relapsed hepatitis C infection, or systematic check-up 1 year after the transplant.
RESULTS: C4d expression was common in biopsies classified as acute rejection (33%) and chronic rejection (100%). C4d was never detected in the event of recurrent hepatitis C infection without rejection.
CONCLUSION: These results, which are comparable to recently published data, give credence to the theory that C4d could be used as a marker for rejection following hepatic transplantation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980082     DOI: 10.1016/j.transproceed.2006.06.120

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

1.  Critical role of effector macrophages in mediating CD4-dependent alloimmune injury of transplanted liver parenchymal cells.

Authors:  Phillip H Horne; Jason M Zimmerer; Mason G Fisher; Keri E Lunsford; Gyongyi Nadasdy; Tibor Nadasdy; Nico van Rooijen; Ginny L Bumgardner
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

Review 2.  Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review.

Authors:  Francesco Vasuri; Deborah Malvi; Elisa Gruppioni; Walter F Grigioni; Antonia D'Errico-Grigioni
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

3.  Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay.

Authors:  Omar Massoud; Julie Heimbach; Kimberly Viker; Anuradha Krishnan; John Poterucha; William Sanchez; Kymberly Watt; Russell Wiesner; Michael Charlton
Journal:  Liver Transpl       Date:  2011-06       Impact factor: 5.799

4.  The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.

Authors:  A I Musat; R M Agni; P Y Wai; J D Pirsch; D F Lorentzen; A Powell; G E Leverson; J M Bellingham; L A Fernandez; D P Foley; J D Mezrich; A M D'Alessandro; M R Lucey
Journal:  Am J Transplant       Date:  2011-03       Impact factor: 8.086

5.  Quantification of C4d deposition and hepatitis C virus RNA in tissue in cases of graft rejection and hepatitis C recurrence after liver transplantation.

Authors:  Alice Tung Wan Song; Evandro Sobroza de Mello; Venâncio Avancini Ferreira Alves; Norma de Paula Cavalheiro; Carlos Eduardo Melo; Patricia Rodrigues Bonazzi; Fatima Mitiko Tengan; Maristela Pinheiro Freire; Antonio Alci Barone; Luiz Augusto Carneiro D'Albuquerque; Edson Abdala
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-02-13       Impact factor: 2.743

6.  B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure.

Authors:  Patrizia Farci; Giacomo Diaz; Zhaochun Chen; Sugantha Govindarajan; Ashley Tice; Liane Agulto; Stefania Pittaluga; Denali Boon; Claro Yu; Ronald E Engle; Mark Haas; Richard Simon; Robert H Purcell; Fausto Zamboni
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.